Delphine Diagnostics Takes Center Stage at NJ Cores Partnering Conference
Princeton, NJ. June 2023:Delphine Diagnostics, a pioneering figure in advanced medical diagnostics, proudly showcased its commitment to scientific collaboration and innovation at the recently concluded New Jersey Research Cores Partnering Conference held this June. The conference brought together leading minds and emerging talents from across the state, with Delphine’s Founder, Andy Bala, and a team comprising Student Interns Isis Gonzalez and Iram Contractor spearheading the company’s representation.
With a focus on nurturing partnerships and igniting transformative ideas, this event was a significant step toward fostering a vibrant scientific community within the region. Delphine Diagnostics seized this occasion to not only share its groundbreaking work but also to establish enduring connections that promise to enrich the scientific landscape.
A notable highlight of the conference was Mr. Bala’s participation as a distinguished panelist. As one of the select Life Sciences startup Eco System Founders from New Jersey, he lent his insights to a discussion centered around the Success Stories of the CSIT Voucher Program. Delphine’s engagement with this program has been pivotal in advancing its cutting-edge research, particularly in enhanced diagnostics, benefitting patients across the global healthcare spectrum.
Delphine Diagnostics expressed its gratitude towards the New Jersey Commission on Science Innovation and Technology Organization (NJ CSIT) for providing this invaluable platform. The exposure garnered from the conference has not only underscored Delphine’s dedication to elevating healthcare standards but has also paved the way for the forthcoming launch of a groundbreaking product – the Sepsis Diagnostics Assay. This revolutionary assay holds the potential to redefine the standard of care for sepsis patients, offering a lifeline that could save countless lives and shield those at risk from this formidable condition.
As Delphine Diagnostics continues to push the boundaries of medical diagnostics, its participation in the NJ Cores Partnering Conference stands as a testament to the company’s unwavering commitment to collaboration, innovation, and ultimately, to the betterment of global healthcare outcomes.
———————
Great news!
Delphine is thrilled to announce that our brilliant Scientist, Dr. Mary Stack, has recently been awarded a grant from the prestigious New Jersey Innovation and Research Fellowship Program. This remarkable achievement brings a wave of excitement to our entire team!
The Innovation and Research Fellowship Program (IRFP) grant serves as a beacon of support for technological research and the thriving innovation ecosystem in New Jersey. With this grant, Delphine aims to revolutionize the field of diagnostic testing with our highly anticipated Sepsis Diagnostic Assay.
Sepsis, a severe and life-threatening condition, demands prompt detection and treatment. However, the current gold standard of blood culture can take up to a painstaking 72 hours to provide results. But fear not! Delphine’s innovative Sepsis Diagnostic Assay seeks to dramatically reduce the time-to-diagnosis to a mere 4 hours, comparable to the swift pace of nucleic acid amplification.
At Delphine Diagnostics, our unwavering focus revolves around identifying and commercializing advancements in diagnostic testing. We wholeheartedly believe that accurate and speedy diagnoses play a vital role in combatting infectious diseases. By improving the accuracy and efficiency of diagnostic tests, we strive to make a significant impact on public health and well-being.
We are bursting with joy and pride as we embark on this groundbreaking journey alongside Dr. Mary Stack. Her dedication and expertise are invaluable assets to our team, and we are confident that her groundbreaking research will pave the way for a brighter future in the field of sepsis diagnosis.
Stay tuned for more updates as we work tirelessly to bring this revolutionary Sepsis Diagnostic Assay to the forefront of medical advancements. Together, let’s shape a world where rapid and accurate diagnostic testing saves lives and brings hope to those in need!
Cheers,
The Delphine Diagnostics Team
*Dr. Stack, the fifth person from the left in the picture
———–
Delphine Diagnostics is at the Roundtable Discussion in Camden
Camden, NJ. April 2023: New Jersey’s Commission on Science, Innovation, and Technology (CSIT) recently organized a valuable event at Rutgers and Rowan University’s Translational Research Facility in Camden, NJ during the last quarter. Delphine Diagnostics was invited to participate in this state-level round table discussion to address pressing issues and challenges facing the life sciences ecosystem.
During the discussion, two key topics were explored:
Q1: Support from the State – What specific type of support would be most impactful for companies like Delphine Diagnostics to grow their business in New Jersey?
Q2: Talent Acquisition – What specific positions do companies like Delphine Diagnostics need to fill for current vacancies and projected future hiring needs to support their growth?
After the discussion, a follow-up communication was shared earlier this month, which included actionable items to address the concerns raised during the round table. Overall, the event proved to be a valuable opportunity for Delphine Diagnostics and other life sciences companies to engage with CSIT and discuss critical issues facing their industry in New Jersey.
Delphine Diagnostics is very grateful to the Executive Leadership and Organizing Committee Members of NJ CSIT, NJ EDA, and NJ DOL for their efforts in organizing this valuable event. It’s clear that this is a positive trend and the engaging and value-add conversation provided an excellent opportunity for industry leaders to come together and discuss critical issues facing the life sciences ecosystem in New Jersey.
The collaborative efforts of these organizations are appreciated and demonstrate a commitment to supporting companies like Delphine Diagnostics as they work to grow and develop within the state. We are grateful for the opportunity to participate in this round table discussion and look forward to continued engagement with NJ CSIT, NJ EDA, and NJ DOL in the future.
————
Panel on Use of Academic and Federal Core Research/Lab Facilities in New Jersey
Princeton, NJ. March 15, 2023: The panel discussion on “Use of Academic and Federal Core Research/Lab Facilities in New Jersey” was a highly informative and beneficial event we recently attended. The panelists were experts in their respective fields. They provided valuable insights into how to access New Jersey’s academic, federal, and nonprofit core labs to accelerate research and development through the Commission on Science Innovation and Technology’s Catalyst and Clean Tech R&D Voucher Grant Program.
The panel was comprised of distinguished individuals such as Vince Smeraglia from Rutgers University, Alex Norman from Princeton University, Irene Wei from CSR Pharma Group, Frances Keel from CSIT, and Nyron Khan from Six Therapeutics. They shared their expertise and answered several questions from the audience, which included entrepreneurs, startup founders, and early-stage firms.
Judith Sheft initiated the panel discussion from CSIT, and Mahako Etta from the same organization moderated the event. The panel was hosted at the Biolabs facility in Princeton, which provided an ideal setting for the discussion.
Overall, the panel discussion provided several key takeaways that will be invaluable for founders of NJ-based startups and early-stage firms. The event was well-organized and highly informative, and we would like to thank the organizers and hosts for their efforts in putting together such a value-added event.
